{"id":5719,"date":"2022-08-01T08:38:55","date_gmt":"2022-08-01T13:38:55","guid":{"rendered":"https:\/\/labtesting.\/?p=5719"},"modified":"2023-08-29T08:39:07","modified_gmt":"2023-08-29T13:39:07","slug":"what-is-ind-enabling-testing-what-does-it-include","status":"publish","type":"post","link":"https:\/\/labtesting.\/2022\/08\/01\/what-is-ind-enabling-testing-what-does-it-include\/","title":{"rendered":"What Is IND-Enabling Testing & What Does It Include? \u00a0"},"content":{"rendered":"\n

IND-enabling testing is a cornerstone of the drug development process, helping researchers predict safety concerns and estimate safe and efficacious starting doses for clinical trials. Planning ahead, understanding the tests you need to conduct, and diligent tracking of all activities are critical to maximize the potential of your IND program.<\/strong><\/p>\n\n\n\n

An Investigational New Drug (IND) application is the first regulatory step drug developers must take when preparing an investigational drug for human clinical studies. According to the Food and Drug Administration (FDA<\/a>), IND applications must include:<\/p>\n\n\n\n

    \n
  1. Animal pharmacology and toxicology studies<\/li>\n\n\n\n
  2. Manufacturing information<\/li>\n\n\n\n
  3. Clinical protocols and investigator information<\/li>\n<\/ol>\n\n\n\n

    In this blog, we take a closer look at #1 \u2013 the studies required in an IND \u2013 as well as tips for planning IND-enabling testing to ensure a complete submission.<\/p>\n\n\n\n

    What Is IND-Enabling Testing?<\/h2>\n\n\n\n

    During a new drug\u2019s early preclinical development<\/a>, sponsors have to demonstrate that a compound is reasonably safe for initial use in humans and exhibits pharmacological activity that justifies commercial development.<\/p>\n\n\n\n

    Data gathered in a series of IND-enabling tests to establish preclinical safety are required to begin first-in-human (FIH)\/Phase 1 studies.<\/p>\n\n\n\n

    IND-enabling testing routinely includes a series of toxicology studies in two species with supporting pharmacokinetic and bioanalytical data, safety pharmacology studies and genetic toxicology. However, a comprehensive IND-enabling program is dependent on your full clinical plan: class of drug, route of administration, dose, duration of treatment and planned indication. <\/p>\n\n\n\n

    What Does IND-Enabling Testing Include? 3 Key Categories<\/h2>\n\n\n\n

    Generally, there are 3 main categories that IND-enabling studies fall under.  <\/p>\n\n\n\n

    #1. Drug Metabolism and Pharmacokinetics (DMPK)<\/h3>\n\n\n\n

    DMPK studies play an important role<\/a> in providing a thorough examination of the absorption, distribution, metabolism and excretion (ADME<\/a>) properties of an experimental drug. Obtaining this information in the preclinical stage helps researchers guide chemical structure optimization and predict in vivo<\/em> PK properties and drug-drug interaction (DDI) potential in humans<\/a>.<\/p>\n\n\n\n

    DMPK studies start in vitro<\/em><\/a> with:<\/p>\n\n\n\n